Adma Biologics Outperforms Market Amidst Revenue Growth Projections

Adma Biologics (ADMA) stock ended at $18.34, up 2.98% from the previous day's close. The company is forecasted to report an EPS of $0.14 and revenue of $121.1 million in its upcoming release, marking a 7.69% and 12.98% increase from the same quarter last year. The Zacks Rank system has a proven track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. ADMA currently has a Zacks Rank of #4 (Sell) and a Forward P/E ratio of 29.2, which is premium compared to its industry's average.

Adma Biologics (ADMA) stock ended the recent trading session at $18.34, demonstrating a +2.98% change from the previous day's close. The stock outpaced the S&P 500's daily gain of 0.61% and the Dow's gain of 0.49%. The technology-centric Nasdaq increased by 0.95%. Coming into today, shares of the infectious disease drug developer had lost 14.62% in the past month. In that same time, the Medical sector lost 0.67%, while the S&P 500 gained 3.85%.

Market participants will be closely following the financial results of Adma Biologics in its upcoming release. The company is forecasted to report an EPS of $0.14, showcasing a 7.69% upward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $121.1 million, indicating a 12.98% increase compared to the same quarter of the previous year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.61 per share and revenue of $505.8 million. These totals would mark changes of +24.49% and +18.61%, respectively, from last year.

The Zacks Rank system has a proven track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Adma Biologics currently has a Zacks Rank of #4 (Sell) and a Forward P/E ratio of 29.2, which is premium compared to its industry's average. The Medical - Biomedical and Genetics industry is part of the Medical sector and carries a Zacks Industry Rank of 75, placing it within the top 31% of over 250 industries.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-adma-biologics-inc-nasdaqadma-shares-bought-by-principal-financial-group-inc-2025-07-09/
[2] https://www.nasdaq.com/articles/adma-biologics-adma-outperforms-broader-market-what-you-need-know